Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosaroxin with Azacitidine in Older AML/MDS-EB-2
NCT03338348Phase 2Completed
- Sponsor
- Ulm University
- Start
- Apr 2018
- Primary completion
- Oct 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of vosaroxin in acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2 (MDS-EB-2), sponsored by Ulm University. Started Apr 2018; status: completed.
02
Drugs
vosaroxin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome with excess blasts-2 (MDS-EB-2)
Beyond the preview
Go deeper on NCT03338348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338348.